Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial

scientific article

Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1016/S1470-2045(16)00150-9
P3181OpenCitations bibliographic resource ID3481819
P698PubMed publication ID27108243

P50authorAlberto BardelliQ28321691
Andrea Sartore-BianchiQ28321693
Salvatore SienaQ28321703
Paolo M. ComoglioQ37381902
Andrea BertottiQ37831180
Silvio Marco VeroneseQ39051644
Silvia MarsoniQ42882462
Daniele ReggeQ43198572
Angelo VanzulliQ43295970
Sara LonardiQ50876272
Francesca BergamoQ52682305
Giulia SiravegnaQ56862949
Vittorina ZagonelQ56925944
Ilaria DepetrisQ56999753
Cosimo MartinoQ61307821
A AmatuQ82728305
Francesco LeoneQ88197017
Livio TrusolinoQ88370775
Valter TorriQ90627606
Patrizia RaccaQ115139909
Katia BencardinoQ117279618
Calogero LauricellaQ117805144
P2093author name stringFortunato Ciardiello
Emanuele Valtorta
Silvia Ghezzi
Giovanna Marrapese
Teresa Troiani
Erika Martinelli
Laura Palmeri
Andrea Cassingena
P2860cites workCancer genome landscapesQ22242276
Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximabQ24600031
Comprehensive molecular characterization of human colon and rectal cancerQ24630415
Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancerQ27851549
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialQ27851578
A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancerQ27851787
HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patientsQ27852057
Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.Q27852316
Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 studyQ28238311
The meaning and use of the area under a receiver operating characteristic (ROC) curveQ29547182
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trialQ29620127
An introduction to recursive partitioning: rationale, application, and characteristics of classification and regression trees, bagging, and random forestsQ30496268
Evaluating the yield of medical testsQ34277948
Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal CancerQ34501536
Oncogene addiction as a foundational rationale for targeted anti-cancer therapy: promises and perilsQ36038823
Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancerQ36432094
The genomic landscape of response to EGFR blockade in colorectal cancer.Q36930106
Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancerQ37378581
Biomarkers of drugs targeting HER-family signalling in cancer.Q38150774
Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolutionQ38257912
Assessment of a HER2 scoring system for colorectal cancer: results from a validation studyQ38384113
Metastatic colorectal cancer: current state and future directionsQ38445676
Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas.Q38841950
Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trialQ40931820
High HER2 expression correlates with response to the combination of lapatinib and trastuzumab.Q41735415
Randomized trial of TAS-102 for refractory metastatic colorectal cancerQ41741632
Low overexpression of HER-2/neu in advanced colorectal cancer limits the usefulness of trastuzumab (Herceptin) and irinotecan as therapy. A phase II trialQ45217739
Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features.Q45938699
Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort studyQ46465639
Sample size tables for exact single-stage phase II designsQ47216643
A 21-year-old patient with a HER2-positive colorectal cancer.Q53038276
Marked response to single agent trastuzumab in a patient with metastatic HER-2 gene amplified rectal cancerQ84419743
P433issue6
P921main subjecttrastuzumabQ412616
multicenter clinical trialQ6934595
colorectal cancerQ188874
colorectal carcinomaQ25493920
phase II clinical trialQ42824440
metastatic colon cancerQ108566365
P304page(s)738-746
P577publication date2016-06-01
P1433published inLancet Oncology CommissionQ13747613
P1476titleDual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial
P478volume17

Reverse relations

cites work (P2860)
Q90843197A practical guide to biomarkers for the evaluation of colorectal cancer
Q90702699A systematic review of salvage therapies in refractory metastatic colorectal cancer
Q52371842Accelerating Therapeutic Development through Innovative Trial Design in Colorectal Cancer.
Q93159538Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer
Q38650454Anti-EGFR monoclonal antibody panitumumab for the treatment of patients with metastatic colorectal cancer: an overview of current practice and future perspectives.
Q97525750Anti-EGFR therapy in metastatic colorectal cancer: mechanisms and potential regimens of drug resistance
Q91622958Anti-tumor activity of antibody drug conjugate targeting aspartate-β-hydroxylase in pancreatic ductal adenocarcinoma
Q89746060BRAF mutant colorectal cancer: ErbB2 expression levels as predictive factor for the response to combined BRAF/ErbB inhibitors
Q39453583Biologics in bowel cancer
Q91754859Biomarker-guided therapy for colorectal cancer: strength in complexity
Q55113382Biomarkers in Urachal Cancer and Adenocarcinomas in the Bladder: A Comprehensive Review Supplemented by Own Data.
Q64250623CAR-T with License to Kill Solid Tumors in Search of a Winning Strategy
Q27612411CIViC database
Q39012229Cancer predisposition syndromes: lessons for truly precision medicine
Q91742610Circulating tumor DNA in colorectal cancer: opportunities and challenges
Q91892015Clinical Implications of Sub-grouping HER2 Positive Tumors by Amplicon Structure and Co-amplified Genes
Q54980136Clinical Utility of Analyzing Circulating Tumor DNA in Patients with Metastatic Colorectal Cancer.
Q102059072Clinical impact of primary tumour location, early tumour shrinkage, and depth of response in the treatment of metastatic colorectal cancer with first-line chemotherapy plus cetuximab or bevacizumab
Q41545171Clinical utility of circulating cell-free DNA in advanced colorectal cancer
Q64229063Colorectal Cancer Biomarkers in the Era of Personalized Medicine
Q90834049Colorectal cancer
Q55306266Colorectal cancer genomics and designing rational trials.
Q55411157Colorectal cancer: genetic abnormalities, tumor progression, tumor heterogeneity, clonal evolution and tumor-initiating cells.
Q92522562Combined blockade of MEK and PI3KCA as an effective antitumor strategy in HER2 gene amplified human colorectal cancer models
Q93128612Combined targeting of HER-2 and HER-3 represents a promising therapeutic strategy in colorectal cancer
Q52603962Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas.
Q46185591Comparative molecular analyses of left-sided colon, right-sided colon, and rectal cancers.
Q60926921Comparisons of metastatic patterns of colorectal cancer among patients by age group: a population-based study
Q54976942Composite regulation of ERK activity dynamics underlying tumour-specific traits in the intestine.
Q90699218Comprehensive review of targeted therapy for colorectal cancer
Q91704285Comprehensive routine diagnostic screening to identify predictive mutations, gene amplifications, and microsatellite instability in FFPE tumor material
Q39066439Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer
Q50105696Copy number profiles of paired primary and metastatic colorectal cancers
Q40411498Copy number variations in DCC/18q and ERBB2/17q are associated with disease-free survival in microsatellite stable colon cancer
Q92256962Current Update of Laboratory Molecular Diagnostics Advancement in Management of Colorectal Cancer (CRC)
Q89993964Current and Future Horizons of Patient-Derived Xenograft Models in Colorectal Cancer Translational Research
Q38787244Current and future biomarkers in the treatment of colorectal cancer.
Q90437250Current challenges in the implementation of precision oncology for the management of metastatic colorectal cancer
Q39172118Current companion diagnostics in advanced colorectal cancer; getting a bigger and better piece of the pie
Q99406919Delivery of Personalized Care for Locally Advanced Rectal Cancer: Incorporating Pathological, Molecular Genetic, and Immunological Biomarkers Into the Multimodal Paradigm
Q64076253Detection of (HER2) Gene Amplification Events in Cell-Free DNA and Response to Anti-HER2 Agents in a Large Asian Cancer Patient Cohort
Q33898865Detection of an ALK Fusion in Colorectal Carcinoma by Hybrid Capture-Based Assay of Circulating Tumor DNA.
Q47437634Determining personalized treatment by gene expression profiling in metastatic breast carcinoma patients: a pilot study.
Q50893422Development of Phosphorothioate DNA and DNA Thioaptamers.
Q57183898Dual HER2 inhibition strategies in the management of treatment-refractory metastatic colorectal cancer: History and status
Q92150346Dual-targeting strategy using trastuzumab and lapatinib in a patient with HER2 gene amplification in recurrent metachronous metastatic gallbladder carcinoma
Q90392916Dynamic monitoring of HER2 amplification in circulating DNA of patients with metastatic colorectal cancer treated with cetuximab
Q58783221Eastern Canadian Colorectal Cancer Consensus Conference 2017
Q52668202Efficacy of histology-agnostic and molecularly-driven HER2 inhibitors for refractory cancers.
Q38941928Emerging tyrosine kinase inhibitors for the treatment of metastatic colorectal cancer
Q58106214Enrichment of Amplification in Brain Metastases from Primary Gastrointestinal Malignancies
Q92185841Evaluating the recent developments in palliative chemotherapy for metastatic colorectal cancer
Q33607015FCγ Chimeric Receptor-Engineered T Cells: Methodology, Advantages, Limitations, and Clinical Relevance
Q53702883First-Line Cetuximab Monotherapy in KRAS/NRAS/BRAF Mutation-Negative Colorectal Cancer Patients.
Q38786707From tumour heterogeneity to advances in precision treatment of colorectal cancer
Q91904078Gene expression profiles of CMS2-epithelial/canonical colorectal cancers are largely driven by DNA copy number gains
Q38676702Genetic and epigenetic markers in colorectal cancer screening: recent advances
Q64235344Genomic Assessment of Blood-Derived Circulating Tumor DNA in Patients With Colorectal Cancers: Correlation With Tissue Sequencing, Therapeutic Response, and Survival
Q90643842Genomic profiling of cell-free circulating tumor DNA in patients with colorectal cancer and its fidelity to the genomics of the tumor biopsy
Q90257585Guardant360 Circulating Tumor DNA Assay Is Concordant with FoundationOne Next-Generation Sequencing in Detecting Actionable Driver Mutations in Anti-EGFR Naive Metastatic Colorectal Cancer
Q50115014HER kinase inhibition in patients with HER2- and HER3-mutant cancers
Q37708897HER-2 inhibition in gastric and colorectal cancers: tangible achievements, novel acquisitions and future perspectives
Q92885759HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal Cancer
Q89868898HER2 and BRAF mutation in colorectal cancer patients: a retrospective study in Eastern China
Q90593024HER2 status in patients with residual rectal cancer after preoperative chemoradiotherapy: the relationship with molecular results and clinicopathologic features
Q90242172HER2-targeted therapies - a role beyond breast cancer
Q49832628Hybrid capture-based genomic profiling of circulating tumor DNA from patients with advanced cancers of the gastrointestinal tract or anus.
Q41548672Identification and characterization of a novel SCYL3-NTRK1 rearrangement in a colorectal cancer patient
Q92830547Immunohistochemistry-Enabled Precision Medicine
Q92316369Immunotherapies and Targeted Therapies in the Treatment of Metastatic Colorectal Cancer
Q91666453Impact of Consensus Molecular Subtype on Survival in Patients With Metastatic Colorectal Cancer: Results From CALGB/SWOG 80405 (Alliance)
Q90292724Impact of Patient Age on Molecular Alterations of Left-Sided Colorectal Tumors
Q47132740Impact of the individualization of the first-line chemotherapy for advanced colorectal cancer based on collagen gel droplet-embedded drug sensitivity test
Q64994221Importance of genetic screens in precision oncology.
Q55116636In the literature: May 2016.
Q52648328Inhibition of Wntless/GPR177 suppresses gastric tumorigenesis.
Q39095733Interrogating open issues in cancer precision medicine with patient-derived xenografts.
Q42925962Intratumoral heterogeneity and clonal evolution in blood malignancies and solid tumors
Q64947645Longitudinal Liquid Biopsy and Mathematical Modeling of Clonal Evolution Forecast Time to Treatment Failure in the PROSPECT-C Phase II Colorectal Cancer Clinical Trial.
Q52592641MODUL-a multicenter randomized clinical trial of biomarker-driven maintenance therapy following first-line standard induction treatment of metastatic colorectal cancer: an adaptable signal-seeking approach.
Q55032398Management of metastatic colorectal cancer patients: guidelines of the Italian Medical Oncology Association (AIOM).
Q28076490Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer
Q58754996Membrane expression of thymidine kinase 1 and potential clinical relevance in lung, breast, and colorectal malignancies
Q59803127Metastatic Colorectal Cancer in the Era of Personalized Medicine: A More Tailored Approach to Systemic Therapy
Q91831000Metastatic colorectal cancer: therapeutic options for treating refractory disease
Q97587469Modern therapeutic approaches for the treatment of malignant liver tumours
Q90644223Molecular Approaches to Metastatic Colorectal Cancer: Better Diagnosis - Better Treatment?
Q58700723Molecular Diagnostics in Clinical Oncology
Q88541726Molecular Landscape of ERBB2/ERBB3 Mutated Colorectal Cancer
Q37710556Molecular Testing for Gastrointestinal Cancer.
Q59794745Molecular characterization and biomarker identification in colorectal cancer: Toward realization of the precision medicine dream
Q50037194Molecular characterization of ERBB2-amplified colorectal cancer identifies potential mechanisms of resistance to targeted therapies: A report of two instructive cases
Q28076360Molecular pathology of cancer: how to communicate with disease
Q91786652Molecular profile in Paraguayan colorectal cancer patients, towards to a precision medicine strategy
Q41091941Molecular profiling of metastatic colorectal tumors using next-generation sequencing: a single-institution experience
Q98386286Molecular subtypes and the evolution of treatment management in metastatic colorectal cancer
Q91689913Molecularly annotation of mouse avatar models derived from patients with colorectal cancer liver metastasis
Q38690672Multi-omics of 34 colorectal cancer cell lines - a resource for biomedical studies
Q38376337Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of KRAS Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers
Q90190001Negative Hyperselection of Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer Who Received Panitumumab-Based Maintenance Therapy
Q50089419Negative hyper-selection of metastatic colorectal cancer patients for anti-EGFR monoclonal antibodies: the PRESSING case-control study
Q55518643Nuclear Klf4 accumulation is associated with cetuximab drug-resistance and predicts poor prognosis of nasopharyngeal carcinoma.
Q92912017Off-label use of common predictive biomarkers in gastrointestinal malignancies: a critical appraisal
Q55342871Optimising the use of cetuximab in the continuum of care for patients with metastatic colorectal cancer.
Q91831006Optimizing biologic sequencing in metastatic colorectal cancer: first line and beyond
Q89782341PIK3R1W624R Is an Actionable Mutation in High Grade Serous Ovarian Carcinoma
Q53360410POLE mutations in colorectal cancer: a new biomarker?
Q92280751Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study
Q38679229Pharmacogenomics of Targeted Agents for Personalization of Colorectal Cancer Treatment
Q39223563Plasticity of Resistance and Sensitivity to Anti-Epidermal Growth Factor Receptor Inhibitors in Metastatic Colorectal Cancer.
Q38698206Pooled Analysis of Clinical Outcome of Patients with Chemorefractory Metastatic Colorectal Cancer Treated within Phase I/II Clinical Studies Based on Individual Biomarkers of Susceptibility: A Single-Institution Experience
Q64903410Potential predictive biomarkers in locally advanced rectal cancer treated with preoperative chemo-radiotherapy.
Q92841164Precision medicine for gastrointestinal cancer: Recent progress and future perspective
Q92280765Precision oncology giveth and precision oncology taketh away
Q39453559Predictive and prognostic biomarkers in personalized gastrointestinal cancer treatment
Q38648300Present and future of metastatic colorectal cancer treatment: A review of new candidate targets
Q90513170Prevalence, prognosis and predictive status of HER2 amplification in anti-EGFR-resistant metastatic colorectal cancer
Q38816712Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer: results from two randomized first-line panitumumab studies.
Q88646346Promising New Agents for Colorectal Cancer
Q49796158Rapid symptomatic relief of HER2-positive gastric cancer leptomeningeal carcinomatosis with lapatinib, trastuzumab and capecitabine: a case report
Q38803202Rationally co-targeting divergent pathways in KRAS wild-type colorectal cancers by CANscript technology reveals tumor dependence on Notch and Erbb2.
Q57821644Recent advances in understanding colorectal cancer
Q41105389Recent developments in the treatment of metastatic colorectal cancer.
Q93375221Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial
Q94076600Relationships between tumour response and primary tumour location, and predictors of long-term survival, in patients with RAS wild-type metastatic colorectal cancer receiving first-line panitumumab therapy: retrospective analyses of the PRIME and PE
Q92381922Report from the 20th annual Western Canadian Gastrointestinal Cancer Consensus Conference; Saskatoon, Saskatchewan; 28-29 September 2018
Q64239421Revisiting Epidermal Growth Factor Receptor () Amplification as a Target for Anti-EGFR Therapy: Analysis of Cell-Free Circulating Tumor DNA in Patients With Advanced Malignancies
Q39455125Role of ADAM10 in intestinal crypt homeostasis and tumorigenesis
Q28068817Role of targeted therapy in metastatic colorectal cancer
Q90711036Safety and efficacy of regorafenib in patients with treatment-refractory metastatic colorectal cancer in Turkey: the single-arm, open-label REGARD study
Q64114423Selecting treatment options in refractory metastatic colorectal cancer
Q55088555Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case.
Q92526836Serial Monitoring of Circulating Tumor DNA in Patients With Metastatic Colorectal Cancer to Predict the Therapeutic Response
Q90724422Serial mutational tracking in surgically resected locally advanced colorectal cancer with neoadjuvant chemotherapy
Q91291948Somatic mutation profiling and HER2 status in KRAS-positive Chinese colorectal cancer patients
Q48219440Suggestion of added value by bevacizumab to chemotherapy in patients with unresectable or recurrent small bowel cancer.
Q42385734Taking aim at the genomic diversity of gastrointestinal cancers: a changing landscape
Q38961110Targeted Therapies in Elderly Patients with Metastatic Colorectal Cancer: A Review of the Evidence.
Q90183323Targeted multiplex proteomics for molecular prescreening and biomarker discovery in metastatic colorectal cancer
Q49417294Targeted next generation sequencing in Chinese colorectal cancer patients guided anti-EGFR treatment and facilitated precision cancer medicine
Q41340207Targeted therapies for gastric cancer: failures and hopes from clinical trials
Q37743048Targeted therapies in breast cancer: New challenges to fight against resistance
Q92747984Targeted therapy for colorectal cancer metastases: A review of current methods of molecularly targeted therapy and the use of tumor biomarkers in the treatment of metastatic colorectal cancer
Q99408604Targeting ERBB2 (HER2) Amplification Identified by Next-Generation Sequencing in Patients With Advanced or Metastatic Solid Tumors Beyond Conventional Indications
Q48234912Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3.
Q30315224Targeting HER2: precision oncology for colorectal cancer
Q54962247Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer.
Q57175806The Clinical Landscape of Circulating Tumor DNA in Gastrointestinal Malignancies
Q64229129The Developing Story of Predictive Biomarkers in Colorectal Cancer
Q92193162The Evolving Biomarker Landscape for Treatment Selection in Metastatic Colorectal Cancer
Q95841155The Quest for Improving Treatment of Cancer of Unknown Primary (CUP) Through Molecularly-Driven Treatments: A Systematic Review
Q42699046The SHIVA01 trial: what have we learned?
Q92181246The Targeted Therapies Era Beyond the Surgical Point of View: What Spine Surgeons Should Know Before Approaching Spinal Metastases
Q58799989The Winding Roadmap of Biomarkers toward Clinic: Lessons from Predictors of Resistance to Anti-EGFRs in Metastatic Colorectal Cancer
Q92462230The impact of panitumumab treatment on survival and quality of life in patients with RAS wild-type metastatic colorectal cancer
Q64065309The landscape of d16HER2 splice variant expression across HER2-positive cancers
Q92785578The past, present, and future of HER2 (ERBB2) in cancer: Approaches to molecular testing and an evolving role in targeted therapy
Q42139529Therapeutic efficacy of SYM004, a mixture of two anti-EGFR antibodies in human colorectal cancer with acquired resistance to cetuximab and MET activation
Q28071772Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence
Q90711354Towards the era of precision medicine in metastatic colorectal cancer
Q30239109Translating genomic profiling to gastrointestinal cancer treatment
Q47560949Trastuzumab Plus Pertuzumab Resistance Does Not Preclude Response to Lapatinib Plus Trastuzumab in HER2-Amplified Colorectal Cancer
Q28077666Trastuzumab in the management of gastroesophageal cancer: patient selection and perspectives
Q64117310Treatment According to Molecular Profiling in Relapsed/Refractory Cancer Patients: A Review Focusing on Latest Profiling Studies
Q88608605Trifluridine/Tipiracil (TAS-102) in Refractory Metastatic Colorectal Cancer: A Multicenter Register in the Frame of the Italian Compassionate Use Program
Q64262617Update on systemic therapy for colorectal cancer: biologics take sides
Q97644005Updates in version 2020 of CSCO guidelines for colorectal cancer from version 2019
Q89326750Validation of a targeted next-generation sequencing approach to detect mismatch repair deficiency in colorectal adenocarcinoma
Q39306576What We Know About Stage II and III Colon Cancer: It's Still Not Enough
Q97424206ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal-Anal Task Forces whitepaper

Search more.